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Impact of graft-versus-host disease after reduced-intensity
conditioning allogeneic stem cell transplantation for acute
myeloid leukemia: a report from the Acute Leukemia Working
Party of the European group for blood and marrow transplantation
F Baron1, M Labopin2, D Niederwieser3, S Vigouroux4, JJ Cornelissen5, C Malm6, LL Vindelov7, D Blaise8, JJWM Janssen9, E Petersen10,
G Socie´11, A Nagler12, V Rocha13,14,17 and M Mohty2,14,15,16,17
This report investigated the impact of graft-versus-host disease (GVHD) on transplantation outcomes in 1859 acute myeloid
leukemia patients given allogeneic peripheral blood stem cells after reduced-intensity conditioning (RIC allo-SCT). Grade I acute
GVHD was associated with a lower risk of relapse (hazards ratio (HR)¼ 0.7, P¼ 0.02) translating into a trend for better overall
survival (OS; HR¼ 1.3; P¼ 0.07). Grade II acute GVHD had no net impact on OS, while grade III–IV acute GVHD was associated
with a worse OS (HR¼ 0.4, Po0.0.001) owing to high risk of nonrelapse mortality (NRM; HR¼ 5.2, Po0.0001). In time-dependent
multivariate Cox analyses, limited chronic GVHD tended to be associated with a lower risk of relapse (HR¼ 0.72; P¼ 0.07) translating
into a better OS (HR¼ 1.8; Po0.001), while extensive chronic GVHD was associated with a lower risk of relapse (HR¼ 0.65; P¼ 0.02)
but also with higher NRM (HR¼ 3.5; Po0.001) and thus had no net impact on OS. In-vivo T-cell depletion with antithymocyte
globulin (ATG) or alemtuzumab was successful at preventing extensive chronic GVHD (Po0.001), but without improving
OS for ATG and even with worsening OS for alemtuzumab (HR¼ 0.65; P¼ 0.001). These results highlight the role of the
immune-mediated graft-versus-leukemia effect in the RIC allo-SCT setting, but also the need for improving the prevention
and treatment of severe GVHD.
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INTRODUCTION
Allogeneic hematopoietic stem cell transplantation (allo-SCT)
following myeloablative conditioning regimen is the treatment
of choice for many young patients with acute myeloid leukemia
(AML).1,2 The antileukemic activity of myeloablative allo-SCT relies
not only on the high dose of chemo/radiotherapy given during
the conditioning regimen, but also on the immune-mediated
graft-versus-leukemia (GVL) effect.1,3,4 The biology of the GVL
effect has been thought to involve reactions to polymorphic
minor histocompatibility antigens expressed either speciﬁcally on
hematopoietic cells (and thus not causing graft-versus-host
disease (GVHD)) or more widely on a number of tissue cells.5,6
Allo-SCT following reduced-intensity conditioning (RIC) is being
increasingly used as treatment for patients with AML who are too
old or too frail to tolerate high-dose conditioning regimens.7–19
The goal of RIC allo-SCT is to harness the GVL effect,7 while
minimizing toxicities and the risk of GVHD. However, this is a
delicate balance as a number of prior studies have shown a
lower risk of relapse in AML patients who experienced chronic
GVHD after RIC allo-SCT compared with those patients who
did not,10–12,20,21 while some other studies failed to ﬁnd such
an association.22,23 A recent analysis from the Center for Inter-
national Blood and Marrow Transplant Research (CIBMTR)
analyzed the impact of GVHD in a cohort of patients with AML
or myelodysplastic syndrome given various graft types after
RIC conditioning.24 In a landmark analysis at 1 year after trans-
plantation (n¼ 630), relapse incidence was reduced only in
the group of patients with prior both acute and chronic GVHD,
while acute and/or chronic GVHD had no signiﬁcant impact
on disease-free survival. With this background, the current report
investigated the impact of occurrence of GVHD and of GVHD
severity on transplantation outcomes in a large cohort of AML
patients given allogeneic peripheral blood stem cells (PBSC)
after RIC.
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This was a retrospective study performed by the Acute Leukemia Working
Party (ALWP) of the European group for Blood and Marrow Transplantation
(EBMT) group. EBMT registry is a voluntary working group of more than
500 transplant centers, participants of which are required to report all
consecutive stem cell transplantations and follow-up once a year. The
scientiﬁc board of the ALWP of EBMT approved this study. Data of adult
AML patients in ﬁrst or second complete remission (CR) at transplantation
and given G-CSF-mobilized PBSCs from HLA-identical sibling (MSD) or
HLA-matched unrelated donors (MUD) between 2000 and 2009 after
RIC were included. Patients given ex-vivo T-cell depleted grafts, those
given other stem cell sources than PBSC, those given pre-emptive donor
lymphocyte infusions and those who failed to engraft (deﬁned as
failure to achieve a sustained engraftment of absolute neutrophil count
of higher than 0.5 109/l; n¼ 34) were excluded. The date and severity
(limited versus extensive) of chronic GVHD (graded according to established
criteria25) were prospectively collected using the EBMT Mimimum Essential
Data-A form.
Patients and conditioning
Data from 1859 patients given PBSC from MSD (n¼ 1208) or MUD
(n¼ 651) were included. Patients’ characteristics are summarized in
Table 1. Brieﬂy, median patient age was 56.3 (range, 18–77) years. Disease
status at allo-SCT was ﬁrst CR in 1439 (77%) patients, while the remaining
420 patients were in second CR. The RIC regimen was based on low-dose
total body irradiation in 520 (28%) patients, while the remaining patients
received chemotherapy-only-based RIC.
Statistical analysis
Cumulative incidence curves were used for relapse incidence and
nonrelapse mortality (NRM) in a competing risk setting, as death and
relapse were competing together.26 For estimating the cumulative
incidence of GVHD, death was considered as a competing event. Overall
(OS) and leukemia-free (LFS) survivals (starting from date of transplant)
were calculated using the Kaplan–Meier estimates; the log-rank test was
used for univariate comparisons. Associations of patient and graft
characteristics with grade II–IV acute GVHD were evaluated using
multivariate logistic regression. Associations of patient and graft char-
acteristics with other outcomes (chronic GVHD, relapse, NRM, LFS and OS)
were evaluated in multivariable analyses, using Cox proportional hazards.
Factors included in the models for acute and chronic GVHD included donor
type, patient age 456 years, female donor to male recipient versus other
gender combinations, donor and recipient cytomegalovirus serostatus,
disease status at the time of transplant, cytogenetic risk group, TBI- versus
chemotherapy-based RIC, the use of antithymocyte globulin (ATG) in the
conditioning, the use of alemtuzumab in the conditioning, center activity27
(arbitrarily deﬁned as center that performed por X20 ﬁrst allo-SCT with
RIC conditioning as treatment for AML between 2000 and 2009) and
prior grade II–IV acute GVHD (for chronic GVHD). The same factors as
well as acute, limited chronic and extensive chronic GVHD were included
in the models for NRM, relapse, LFS and OS (Table 2). The impact
of chronic GVHD on other outcomes was always studied as a time-
dependent variable, and we only considered GVHD occurring before
relapse in the paper. All tests were two sided. The type I error rate was
ﬁxed at 0.05 for determination of factors associated with time to event
outcomes. Statistical analyses were performed with SPSS (SPSS Inc.,




Acute GVHD of grades II, III and IV were observed in 252 (14%), 102
(5%) and 54 (3%) patients, respectively, while grade unknown,
limited and extensive chronic GVHD were observed in 30 (2% of
patients alive at day 100 (n¼ 1545)), 349 (23%) and 391 (25%)
patients, respectively (Table 1). With a median follow-up of 28
(range, 0.5–130) months, 3-year incidences of relapse, NRM, LFS
and OS were 34±1%, 18±1%, 48±1% and 54±1%, respectively.
Supplementary Table S1 shows the factors associated with
outcomes in univariate analyses.
Impact of GVHD on transplantation outcomes
Predictive factors for grade II–IV acute GVHD included unrelated donor
(RR¼ 2.4; 95% CI, 1.8–3.3; Po0.001), intermediate (RR¼ 2.7; 95% CI,
1.3–5.6; P¼ 0.009) or poor risk (RR¼ 2.3; 95% CI, 1.0–5.1; P¼ 0.04)
Table 1. Patients and transplant outcomes
N¼ 1859
Median patient age, years (range) 56.3 (18–77)
Recipient gender (M/F), # M (%)/#F (%) 946 (51)/912 (49)
Donor type # MRD (%)/ # MUDa (%) 1208 (65)/ 651 (35)
Median donor age (range), years 48.6 (12–80)
Donor gender (M/F), #M (%)/#F (%) 1101 (60)/ 742 (40)
Female donor/male recipient, # pts (%) 338 (18)
Median year of SCT, years (range) 2006 (2000–2009)
Status at SCT # CR1 (%)/ # CR2 (%) 1439 (77)/ 420 (23)
Patient CMV seropositivity # (%) 1051 (66)
Donor CMV seropositivity # (%) 885 (56)
Cytogenetics
Good riskb 88 (5)
Intermediate riskc 776 (42)
High riskd 192 (10)
Not reported 803 (43)
Conditioning (RICe), # (%)
Low-dose TBI-based RIC 520 (28)
Fludarabine-melphalan-based RIC 390 (21)
Fludarabine-busulfan-based RIC 654 (35)
Other chemotherapy-based RIC 295 (16)




Center activity, # (%)
Higherf 1408
Lower 451
Grade II–IV acute GVHD, # (%) 408 (22)
Chronic GVHD
Limited chronic GVHD, # (%g) 349 (23)
Extensive chronic GVHD, # (%g) 391 (25)
Chronic GVHD grade unknown, # (%g) 30 (2)
3-year CI of chronic GVHD 47±1
Median (range) time of diagnosis of chronic
GVHD (days)
163 (100–1545)
3-year CI of NRMh (%) 18±1
3-year CI of relapsei (%) 34±1
3-year LFSj (%) 48±1
3-year OS (%) 54±1
Abbreviations: ATG, antithymocyte globulin; CI, cumulative incidence; CMV,
cytomegalovirus; CR1, first complete remission; CR2, second complete
remission; F, female; GVHD, graft-versus-host disease; LFS, leukemia-free
survival; M, male; MRD, HLA-identical related donor; MUD, HLA-matched
unrelated donor; NRM, nonrelapse mortality; OS, overall survival;
RIC, reduced-intensity-conditioning; SCT, stem cell transplantation;
TBI, total body irradiation; #, number of patients. aDefined as 6/6 or 8/8
HLA-allele-matched unrelated donors. bDefined as t(8;21), t(15;17), inv or
del (16), or acute promyelocytic leukemia, these abnormalities only or
combined with others. cDefined as all cytogenetics not belonging to the
good or high risk (including trisomias). dDefined as 11q23 abnormalities,
complex caryotype, and abnormalities of chromosomes 5 and 7. eDefined
as use of fludarabine associated with fewer than 6 Gy (low dose) total-
body irradiation, or busulfan p8mg/kg, or other nonmyeloablative drugs.
fDefined as center that performedX20 first allo-SCT with RIC conditioning
as treatment for acute myeloid leukemia (AML) between 2000 and 2009.
gAmong patients alive at day 100. hDefined as any death without previous
relapse or progression. iDefined as hematologic relapse. jDefined as
survival without evidence of relapse.
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cytogenetics, and absence of in-vivo T-cell depletion with
alemtuzumab (RR¼ 0.5; 95% CI, 0.4–0.8; P¼ 0.004). There was
also a suggestion for lower risk of grade II–IV acute GVHD in
patients given ATG (RR¼ 0.8; 95% CI, 0.5–1.1; P¼ 0.10), although
it did not reach statistical signiﬁcance. In multivariate analysis,
grade I acute GVHD was associated with a lower risk of relapse
(hazards ratio (HR)¼ 0.7, 95% CI, 0.5–0.9; P¼ 0.02) translating into
better LFS (HR¼ 1.3, 95% CI, 1.1–1.7; P¼ 0.01) and a trend for better
OS (HR¼ 1.3, 95% CI, 1.0–1.6; P¼ 0.06). Grade II and grade III–IV acute
GVHD were each associated with a lower risk of relapse (HR¼ 0.7,
95% CI, 0.6–1.0; P¼ 0.05; and HR¼ 0.6, 95% CI, 0.4–1.0, P¼ 0.05,
respectively), but also with a suggestion for higher NRM for grade
II acute GVHD (HR¼ 1.3, 95% CI, 0.9–1.2; P¼ 0.19), and higher NRM
for grade III–IV acute GVHD (HR¼ 5.2, 95% CI, 3.7–7.2; Po0.0001,
respectively) leading a similar OS for grade II acute GVHD
(HR¼ 1.0, 95% CI, 0.8–1.2; P¼ 0.85) and a worse OS for grade
III–IV (HR¼ 0.4, 95% CI, 0.3–0.5; Po0.001) acute GVHD. To further
assess the GVL effect of acute GVHD, we also performed a
landmark analysis in patients who were leukemia-free at 100 days
after transplantation. As shown in the Figure 1, 4-year OS were
Table 2. Multivariate analyses of transplant outcomes
Progression/relapse NRM LFS OS
HRa (95% CI) Pa HRa (95% CI) Pa HRa (95% CI) Pa HRa (95% CI) Pa
No chronic GVHDb (reference) 1 1 1 1
Limited chronic GVHDb 0.7 (0.5–1.0) 0.07 1.5 (0.9–2.3) 0.4 1.1 (0.9–1.5) 0.42 1.8 (1.3–2.4) o0.001
Extensive chronic GVHDb 0.7 (0.5–0.9) 0.02 3.5 (2.4–5.2) o0.001 0.8 (0.6–1) 0.03 1.1 (0.8–1.4) 0.58
Acute GVHD
No acute GVHD (reference) 1 1 1 1
Acute GVHD grade I 0.7 (0.5–0.9) 0.02 0.9 (0.6–1.3) 0.54 1.3 (1.1–1.7) 0.01 1.3 (1–1.6) 0.06
Acute GVHD grade II 0.7 (0.6–1) 0.05 1.3 (0.9–1.2) 0.19 1.1 (0.9–1.4) 0.36 1 (0.8–1.2) 0.85
Acute GVHD grade III–IV 0.6 (0.4–1) 0.05 5.2 (3.7–7.2) o0.001 0.5 (0.4–0.7) o0.001 0.4 (0.3–0.5) o0.001
Use of alemtuzumab versus not 1.5 (1.1–2.1) 0.008 1.4 (1–2.2) 0.08 0.7 (0.5–0.8) 0.001 0.6 (0.5–0.8) 0.001
Use of ATG versus not 1.5 (1.2–2.0) 0.008 0.7 (0.5–1.0) 0.08 0.8 (0.7–1) 0.11 0.9 (0.7–1.2) 0.51
MUD versus MRD 0.9 (0.7–1.1) 0.3 1.94 (1.3–2.7) o0.001 0.9 (0.7–1.1) 0.16 0.8 (0.7–1) 0.11
CR2 versus CR1 1.6 (1.3–2.0) o0.001 1.6 (1.2–2.2) 0.002 0.6 (0.5–0.7) o 0.001 0.6 (0.5–0.8) o0.001
Patient age 456 years 1.1 (0.9–1.4) 0.19 1.3 (1.0–1.7) 0.04 0.8 (0.7–1) 0.03 0.8 (0.7–0.9) 0.01
Female donor to male recipient 0.9 (0.7–1.2) 0.62 1.3 (1.0–1.9) 0.08 1 (0.8–1.2) 0.73 0.9 (0.8–1.2) 0.63
Patient CMV seropositivity 0.9 (0.7–1.1) 0.4 1.1 (0.8–1.5) 0.45 1 (0.9–1.2) 0.97 1.0 (0.8–1.2) 0.98
Donor CMV seropositivity 1.1 (0.9–1.3) 0.67 1.1 (0.8–1.5) 0.48 0.9 (0.8–1.1) 0.43 0.9 (0.8–1.1) 0.40
TBI-based RIC versus not 1.6 (1.2–2) o0.001 0.9 (0.6–1.3) 0.52 0.8 (0.6–0.9) 0.01 0.8 (0.6–1) 0.02
Cytogenetics
Good (reference) 1 1 1 1
Intermediate versus good 2.3 (1.3–3.9) 0.003 1.4 (0.8–2.5) 0.29 0.5 (0.4–0.8) 0.003 0.6 (0.4–0.9) 0.01
Poor versus good 3.6 (2.0–6.4) o0.001 1.23 (0.7–2.8) 0.42 0.4 (0.3–0.6) o0.001 0.4 (0.3–0.7) 0.001
NA versus good 2.2 (1.3–3.8) 0.005 1.7 (0.9–3.2) 0.09 0.5 (0.3–0.8) 0.002 0.5 (0.3–0.8) 0.004
Big centersc 0.7 (0.6–0.9) 0.01 0.7 (0.5–1.0) 0.03 1.3 (1.1–1.6) 0.002 1.3 (1.1–1.5) 0.03
Abbreviations: ATG, antithymocyte globulin; CMV, cytomegalovirus; CR1, first complete remission; CR2, second complete remission; GVHD, graft-versus-host
disease; HR, hazards ratio; LFS, leukemia-free survival; MRD, HLA-identical related donor; MUD, HLA-matched unrelated donor; NA, not applicable;
NRM, nonrelapse mortality; OS, overall survival; RIC, reduced-intensity-conditioning; TBI, total body irradiation. aStatistically significant factors are in bold.
bModeled as a time-dependent event. cArbitrarily defined as a center that performedX20 first allo-SCT with RIC conditioning as treatment for AML between
2000 and 2009.
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Figure 1. (a) Landmark analysis at 100 days after transplantation showing the cumulative incidence of relapse in patients who had no
acute GVHD (continuous line) (at 4 years¼ 34±2%), grade I acute GVHD (broken line — —) (at 4 years¼ 30±3%), grade II acute GVHD
(dotted line - - -) (at 4 years¼ 26±3%), grade III–IV acute GVHD (broken line – - – - –) (at 4 years¼ 17±4%). (b) Landmark analysis
at 100 days after transplantation showing OS in patients who had no acute GVHD (continuous line) (at 4 years¼ 60±2%), grade I acute
GVHD (broken line — — ) (at 4 years¼ 66±2%), grade II acute GVHD (dotted line - - -) (at 4 years¼ 56±4%), grade III–IV acute GVHD
(broken line — - – - – ) (at 4 years¼ 43±4%).
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66±2% in patients with grade I acute GVHD, 60±2% in patients
without acute GVHD, 56±4% in patients with grade II acute GVHD
and 43±4% in patients with grade III–IV acute GVHD.
Predictive factors for extensive chronic GVHD other than acute
GVHD were higher center activity (HR¼ 1.8; 95% CI, 1.3–2.4;
Po0.001), and absence of in-vivo T-cell depletion with ATG
(HR¼ 2.4; 95% CI, 1.7–3.3; Po0.001) or with alemtuzumab
(HR¼ 2.4; 95% CI, 1.6–3.7; Po0.001). In multivariate time-
dependent analyses, occurrence of limited chronic GVHD was
associated with a trend for a lower risk of relapse (HR¼ 0.7;
95% CI, 0.5–1.0; P¼ 0.07), a suggestion for higher NRM (HR¼ 1.5;
95% CI, 0.9–2.3; P¼ 0.4), and signiﬁcantly improved OS (HR¼ 1.8;
95% CI, 1.3–2.4; Po0.001; Figure 2), while occurrence of exten-
sive chronic GVHD was associated with a lower risk of relapse
(HR¼ 0.7; 95% CI, 0.5–0.9; P¼ 0.02), but higher NRM (HR¼ 3.5;
95% CI, 2.4–5.2; Po0.001), and comparable OS (HR¼ 1.1; 95% CI,
0.8–1.4; P¼ 0.58). There was no interaction between the disease
status at transplantation nor the donor type and the impact of
GVHD subtypes on transplantation outcomes. Interestingly, 3-year
NRM (26±3% versus 27±6%; P¼ 0.80) and OS (61±3% versus
63±6%; P¼ 0.78) from diagnosis of extensive chronic GVHD were
comparable in patients transplanted in centers with higher or
lower activity.
To further assess the GVL effect of either chronic GVHD or of
both acute and chronic GVHD, we performed two landmark analyses
in patients who were leukemia-free at 18 months after transplantation
(n¼ 776). In the landmark analysis looking at the impact of chronic
GVHD, patients with chronic GVHD before the landmark day had a
lower relapse rate (Po0.001), higher NRM (Po0.001) and similar
survival than those without chronic GVHD before the landmark
day (Figure 3). For the landmark analysis looking at the impact of
both acute and chronic GVHD, patients were separated into three
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Figure 3. (a) Landmark analysis at 18 months after transplantation showing the cumulative incidence of relapse in patients who had no
chronic GVHD (continuous line), limited chronic GVHD (broken line - - -) or extensive chronic GVHD (dotted line) before 18 months after RIC
allo-SCT. Median follow-up from this landmark day was 24 (range, 0.1–112) months. (b) Landmark analysis at 18 months after transplantation
showing the cumulative incidence of NRM in patients who had no chronic GVHD (continuous line), limited chronic GVHD (broken line - - -) or
extensive chronic GVHD (dotted line) before 18 months after RIC allo-SCT. (c) Landmark analysis at 18 months after transplantation showing
OS in patients who had no chronic GVHD (continuous line), limited chronic GVHD (broken line - - -) or extensive chronic GVHD (dotted line)
before 18 months after RIC allo-SCT.
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Figure 2. ‘Pseudo landmark analysis’20,29 illustrating the impact
of limited chronic GVHD on OS in a time-dependent manner.
The ‘no chronic GVHD line’ (continuous line) shows OS from day 166
after RIC-alloSCT (the median day of onset of limited chronic GVHD)
for patients who never experienced chronic GVHD. The limited chronic
GVHD line (broken line) shows OS from diagnosis of limited chronic
GVHD in patients who experienced limited chronic GVHD anytime after
transplantation. At 3 years, survival was 72±3% in the limited chronic
GVHD group versus 56±2% in the non-GVHD group (Po0.0001).
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groups: a group of patients without any GVHD (no GVHD group),
a group of patients with grade II–IV acute GVHD and/or with
extensive chronic GVHD (severe GVHD group), and a third group
including remaining patients (mild GVHD group). As shown in the
Figure 4, 4-year OS were 88±3% in patients with mild chronic
GVHD, 85±3% in patients without GVHD and 81±2% in patients
with severe GVHD.
Impact of in-vivo depletion with ATG or alemtuzumab on
transplantation outcomes
In multivariate analyses, in-vivo T-cell depletion with ATG was
associated with a higher risk of relapse (HR¼ 1.5; 95% CI, 1.2–2.0;
P¼ 0.008), a trend for lower NRM (HR¼ 0.7; 95% CI, 0.5–1.0;
P¼ 0.08), similar LFS (HR¼ 0.8; 95% CI, 0.7–1.0; P¼ 0.11) and
similar OS (HR¼ 0.9; 95% CI, 0.7–1.2; P¼ 0.51), while in-vivo T-cell
depletion with alemtuzumab was associated with a higher risk of
relapse (HR¼ 1.5; 95% CI, 1.1–2.1; P¼ 0.008), a trend to a higher
risk of NRM (HR¼ 1.4; 95% CI, 1–2.2; P¼ 0.08), a lower LFS
(HR¼ 0.7; 95% CI, 0.5–0.8; P¼ 0.001) and a lower OS (HR¼ 0.6;
95% CI, 0.5–0.8; P¼ 0.001) (Table 2). Finally, there was no
interaction between the disease status at transplantation nor the
donor type and the impact of in-vivo T-cell depletion on
transplantation outcomes.
DISCUSSION
AML control after RIC allo-SCT has been in part attributed to the
immune-mediated GVL effect.28 Given the close relationship
between GVHD and GVL, this study sought to assess the impact
of GVHD on outcome in a large and rather homogeneous cohort
of AML patients given PBSC after various RIC, and particularly at
assessing the impact of GVHD on survival given the divergent
results observed in studies containing fewer number of
patients.10–12,20–24 Several observations could be drawn from the
current ﬁndings.
First, current study observed a positive impact (that is, lower risk
of relapse translating into better LFS) of grade I acute GVHD on
transplantation outcomes in patients given RIC allo-SCT for AML.
This indirectly demonstrates the susceptibility of AML to graft-
versus-tumor effects. In contrast, as observed by other groups of
investigators,10,20,21 current data indicated that grade II acute
GVHD had no net impact on LFS/OS because the lower risk of
relapse in patient with grade II–IV acute GVHD was offset by a
higher NRM, and grade III–IV acute GVHD was associated with
worse LFS/OS.
Second, current data conﬁrmed an association between chronic
GVHD and a lower risk of AML relapse, as observed previously by
other groups of investigators,10,11 but demonstrated that the
beneﬁcial effect of chronic GVHD in terms of survival was
restricted to patients with limited chronic GVHD, given that
extensive chronic GVHD was strongly associated with higher NRM.
As relapse and NRM are competing events, it cannot be excluded
that a part of the lower risk of relapse in patients with extensive
chronic GVHD was due to the competition between the risks of
relapse and NRM rather than to a true antileukemic activity of
extensive chronic GVHD.29
Another important ﬁnding or our study was that attempts at
preventing extensive chronic GVHD by in-vivo T-cell depletion
with ATG or alemtuzumab, although successful at preventing it,
failed to improve OS/LFS owing to a signiﬁcant increase in the
incidence of relapse, even after adjusting for acute and chronic
GVHD, suggesting that donor T cell could mediate GVL effects in
the absence of clinical GVHD, perhaps through graft-versus-host
reactions limited to the recipient hematopoietic system. While
ATG use did not affect OS, the use of alemtuzumab was associated
with signiﬁcantly worse survival, because it did not protect from
NRM. Unfortunately, given the retrospective nature of the study,
we did not have data related to alemtuzumab or ATG dosages for
all patients who were given an alemtuzumab-based or an ATG-
based conditioning. Current results are in accordance with a
recent study from the CIBMTR analyzing data from 1676 patients
given grafts after RIC as treatment for various hematological
malignancies demonstrating that the use of alemtuzumab and/or
ATG was associated with higher risk of relapse, that translated into
worse disease-free survival.30
Patients transplanted in high-activity centers had higher
incidence of chronic GVHD and better outcomes owing to both
lower relapse risk and lower NRM than those transplanted in
lower-activity centers, as previously observed by Giebel et al.27
The higher incidence of chronic GVHD in patients transplanted in
high-activity centers (even after adjusting for the use of ATG or
alemtuzumab) could be due in part at a better recognition of signs
of chronic GVHD in larger transplant centers, or to different modu-
lation strategies of postgrafting immunosuppression according to
disease risk and minimal residual disease data after transplanta-
tion in patients transplanted in high-activity centers (leading to
both lower risk of relapse and higher incidence of chronic GVHD).
Interestingly, NRM in patients diagnosed with extensive chronic
GVHD was similar in patients transplanted in centers with high or
low activity, stressing that treatment of extensive chronic GVHD
has remained a difﬁcult challenge even in large transplant centers.
Years















Figure 4. (a) Landmark analysis at 18 months after transplantation showing the cumulative incidence of relapse in patients who had no GVHD
(continuous line) (at 4 years¼ 20±3%), mild GVHD (broken line — —; defined as grade I acute or limited chronic GVHD) (at 4 years¼ 10±3%)
or severe GVHD (dotted line - - -, defined as grade II–IV acute and/or extensive chronic GVHD) (at 4 years¼ 10±2%) before 18 months after
RIC allo-SCT. (b) Landmark analysis at 18 months after transplantation showing OS in patients who had no GVHD (continuous line)
(at 4 years¼ 85±3%), mild GVHD (broken line — —) (at 4 years¼ 88±3%) or severe GVHD (dotted line- - -) (at 4 years¼ 81±2%) before
18 months after RIC allo-SCT.
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This study also identiﬁed poor risk cytogenetics, being in second
versus in ﬁrst CR, and conditioning with low-dose TBI-based RIC
as being associated with worse LFS or OS, conﬁrming previous
reports.18,31,32 Finally, our study demonstrated higher mortality
in patients above 56 years of age at transplantation in compa-
rison with younger patients, in contrast to what has been
observed in a recent report from the CIBMTR analyzing data
from 545 patients with AML given RIC allo-SCT,18 perhaps because
analyses were not adjusted for comorbidities at transplantation
(more likely to be more frequent in older patients) in current
study.
In conclusion, in this large cohort of AML patients transplanted
in CR using G-CSF-mobilized PBSCs, occurrence of grade I
acute GVHD was associated with a lower incidence of relapse
that translated toward better LFS, while occurrence of chronic
GVHD was associated with a lower risk of relapse that translated
toward improved OS in patients with limited chronic GVHD
but not in those with extensive chronic GVHD who experienced
higher long-term NRM. Overall, these ﬁndings highlight the
close relationship between graft-versus-host reactions and the
potential beneﬁt of the immune-mediated GVL effect in the RIC
allo-SCT setting, but also underline the need for improving
the prevention and treatment of severe GVHD in patients
receiving RIC allo-SCT, perhaps through promoting regulatory
T cells.33,34
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